Parse Biosciences Announces Partnership With Research Instruments Group to Offer RNA-Seq Kits in Singapore and Southeast Asia Region
Previously available in North America, Europe, Australia and New Zealand, partnership to further accelerate single cell genomics research in the APAC region
Seattle, WA, January 18, 2022
Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to provide Parse’s Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits and Nuclei Fixation Kits to markets in Singapore and Southeast Asia.
Under an agreement between the two parties, Research Instruments has been appointed a distributor of the Parse product portfolio for Singapore, Thailand, Malaysia and Vietnam.
Research Instruments will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse Bioscience portfolio of single-cell genomics research.
Research Instruments is the premier distributor for genomic and life science research products in Southeast Asia, with multiple technical teams and established customer support relationships throughout the region. Their core mission is to introduce and accelerate the adoption of groundbreaking life science research tools to their markets.
In early 2021, Parse Biosciences introduced their Whole Transcriptome Kits to the market which features Evercode: their patented technique of combinatorial barcoding. In October 2021, they expanded that offering to include the Evercode Whole Transcriptome Mega, which allows researchers to profile up to 1,000,000 cells in parallel, and the Evercode Whole Transcriptome Mini, a kit used to profile up to 10,000 cells in parallel for smaller-scale studies at an entry-level price point.
“A significant priority for the Parse team is accessibility–not only in how readily customers can start using the technology, but also with a fully supportive team backing their efforts,” said Alex Rosenberg, CEO and Co-founder of Parse Biosciences. “We’re thrilled that Research Instruments shares our vision of offering scalable and easily adaptable single-cell RNA-seq technology to a wide market.”
“At RI, we’re committed to providing access to innovative technologies,” said Greg Kent, CEO of Research Instruments. “The sequencing solutions of Parse Biosciences simplify workflows without sacrificing resolution, and with our technical sales and applications support teams who are trained and experienced in single cell genomics applications, the Parse Bioscience platform now becomes readily accessible to any scientist in the region.”
Parse Biosciences and Research Instruments will be hosting a technical introductory webinar for Southeast Asia on January 20, 2022 at 10:00 AM SGT. Discover more about Parse Biosciences and the capabilities of its platform at https://www.parsebiosciences.com/, or contact Research Instruments at https://www.ri.com.sg/.
About Parse Biosciences
Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.
At the core of our company is our pioneering approach for single cell sequencing. Single-cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
To learn more, please visit: https://www.parsebiosciences.com/.
About Research Instruments
Research Instruments Pte Ltd is a leading distributor of scientific instruments and bio-reagents for life science research, with a focus providing next-generation tools and technologies with best-in-class support for applications, maintenance services and training. Established in 1989 with offices throughout Southeast Asia, Research Instruments Pte Ltd is GDP-MDS certified for Dx and Medical device distribution, bizSAFE for engineering services, and offers GMP compliant and ISO 9001 Certified warehousing and cold-chain logistics for our customers.
For more information, please visit https://www.ri.com.sg/.
Parse Biosciences Unveils 1,000,000 Cell scRNA-seq Kit
The Evercode Whole Transcriptome Mega represents the most scalable and highest resolution single-cell platform to date
Seattle, WA, October 20, 2021
Today at the annual American Society for Human Genetics meeting, Parse Biosciences, a company providing researchers with single-cell sequencing solutions, announced the launch of the most scalable single-cell RNA-seq solution on the market.
The Evercode Whole Transcriptome Mega allows researchers to profile up to 1,000,000 cells in parallel, allowing for unprecedented scale without losing biological resolution or data quality, and without the need for a custom instrument.
“Our one million cell solution represents the next evolution for single-cell sequencing,” said Alex Rosenberg, PhD., CEO and co-founder of Parse Biosciences. “Our kit’s new capabilities allow researchers to unlock a scale and a level of biological resolution never before thought possible. No other platform gives researchers this level of scale or usable data.”
Parse’s newest product addition is based on the same split-pool combinatorial barcoding technology as its 100,000 cell kit previously launched in February 2021, now called the Evercode Whole Transcriptome Kit. By using this unique approach to barcoding cells, Parse is able to bring single cell sequencing to the million-cell scale and offer high levels of sensitivity and gene detection.
Researchers can benefit from the Evercode WTK Mega’s unique capabilities, including:
Unprecedented scalability – Up to 96 unique biological samples and 1,000,000 cells or nuclei in a single experiment.
Increased sensitivity – Parse’s platform demonstrates high transcript detection even in cells with low RNA content.
Increased resolution – A lower doublet rate than anything else on the market (observed doublets of 3.2% for 1M cells). Researchers can trust the data is true single cell data.
Simplified workflow – By separating the sample extraction from downstream library preparation, Parse empowers researchers to run fixed samples collected on different dates or at different locations together in a single experiment.
Easy to get started – Researchers can bypass the need for expensive and complicated microfluidic instruments to get started quickly. There are no maintenance fees or custom instruments required.
Simultaneously, Parse is also announcing the launch of the Evercode Whole Transcriptome Mini, empowering researchers to launch smaller-scale studies where they can profile 10,000 cells in parallel at an affordable price point.
Parse’s flagship product, the Evercode Whole Transcriptome Kit, is currently used by over 150 leading laboratories across the country.
Parse Biosciences will be presenting new capabilities of its platform at this year’s American Society of Human Genetics Meeting from October 18-22, 2021. Don’t miss CTO and co-founder Charlie Roco’s session, “Scaling Single Cell RNA-Seq: The Solution,” where he will unveil the capabilities of Evercode WT Mega and discuss what it means to conduct large-scale scRNA-seq research. ASHG attendees can join virtually on Wednesday, October 20th at 2:30pm Eastern.
You can also learn more or request a quote at: https://www.parsebiosciences.com/evercode-whole-transcriptome-mega.
Parse Biosciences Extends RNA-Seq Kit Reach to Australia and New Zealand through Decode Sciences Agreement
Seattle, WA, October 11, 2021
Under an agreement between the parties, Decode Science has been appointed a distributor of the Parse product portfolio for Australia and New Zealand. Decode Science will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse Whole Transcriptome Kit (WTK), Cell Fixation Kit, and Nuclei Fixation Kit.
Decode Science is the premier distributor for genomic and multi-omic products with established relationships at key accounts in the region. The Decode team takes pride in enabling their customers to publish faster with better results.
Earlier this year, Parse Biosciences introduced split-pool combinatorial barcoding to the market – a disruptive, intrinsically scalable single-cell RNA-seq technology that doesn’t require a separate hardware purchase. The approach, originally demonstrated in a 2018 Science paper with SPLiT-seq, has been substantially improved prior to commercialization.
The Parse Biosciences assay transforms each cell into a unique reaction compartment instead of physically isolating the cells. In addition to providing substantially lower rates of data contamination, referred as multiplets in the industry, sequencing is considerably more efficient and cell size restrictions are eliminated.
The Parse Bioscience WTK assay is the first-in-class single-cell assay that enables the profiling of up to 48 samples and 100,000 cells or nuclei. The Cell and Nuclei Fixation kits enable researchers to fix and store suspensions for up to 6 months – a capability highly desired in the field, especially for time-course studies.
“The Parse team is elated to include Australia and New Zealand in the global expansion,” said Alex Rosenberg, CEO and Cofounder of Parse Biosciences. “We see these markets contributing substantially to our success and found the perfect partner in Decode.”
“Decode Science is excited to bring Parse Biosciences to the Australian and New Zealand life science community,” said Josh Warburton, Managing Director of Decode Science. “Parse Biosciences’ technology moves single-cell results beyond the limitations inherent in current techniques, enabling our customers to publish faster, in higher impact journals.”
Parse Biosciences will be presenting new capabilities of its platform at this year’s American Society of Human Genetics Meeting from October 18-22, 2021. To join, find Parse’s Industry Sessions here. You can also learn more at https://www.parsebiosciences.com/.
Parse Biosciences Launches Whole Transcriptome
Kit to Dramatically Scale Single Cell Sequencing
Now commercially available, the Whole Transcriptome Kit enables researchers in neuroscience, immunology, oncology, as well as other areas of scientific study, to achieve industry-leading detail on cell types and subtypes
Seattle, WA, February 18, 2021
Parse Biosciences., a company providing researchers with scalable and flexible single cell sequencing solutions, today announced the launch of their Single Cell Whole Transcriptome Kit. The kit, which was previously available only through Parse’s early access program, is now generally available to all researchers in North America.
The Whole Transcriptome Kit from Parse Biosciences contains everything needed to run a single cell experiment with 100,000 cells across 48 samples. Previously, single cell sequencing solutions demanded that researchers invest in expensive lab equipment to get started. Now, with the launch of Parse Bioscience’s Whole Transcriptome Kit, researchers have a reliable and scalable, end-to-end single cell sequencing technology that utilizes only basic lab equipment.
“For too long, labs have been held back by technologies that not only compromise on data quality, but which also don’t scale to match researchers’ ambitions,” said Alex Rosenberg, co-founder and CEO of Parse. “Through our Whole Transcriptome Kit, we support researchers who are taking on some of the most challenging problems in biology — spanning neuroscience, immunology, and beyond. We provide them with a technology that is more scalable and offers higher resolution than anything else on the market, including droplet-based solutions.”
Since their pioneering paper on SPLiT-seq published in Science in 2018, Parse Biosciences has continued to refine their technology. The Whole Transcriptome Kit marks a tremendous improvement from the proof-of-concept introduced in the company’s paper, with improved sensitivity and industry-leading data resolution.
Key features of the Single Cell Whole Transcriptome Kit include:
Accommodation of up to 48 unique biological samples and up to 100,000 cells or nuclei with a single kit.
Separation of the sample extraction from downstream library preparation steps empowers researchers to run fixed samples collected on different dates together in a single experiment.
Long-term storage (up to 6 months) of fixed samples — with no impact on gene expression or the number of transcripts detected per cell.
Full compatibility with both cells and nuclei gives researchers the choice on how to prepare their samples
A lower doublet rate than anything else on the market. Researchers can trust the data is true single cell data.
Increased sensitivity enables high transcript detection including cells with low RNA content such as PBMCs.
No custom instrument means researchers can get started quickly with no capital costs. Through split-pool combinatorial barcoding, researchers can bypass the need for expensive and complicated microfluidic instruments.
The Parse Biosciences pipeline is an out-of-the-box software tool that you can run locally to go straight from sequencing files to processed data. The pipeline produces interactive outputs that make it possible to browse gene expression across different biological samples and cell populations.
Through their early access program, Parse Biosciences’ Whole Transcriptome Kit has already been used in 50 labs across the country, providing researchers with improved resolution and throughput in their experiments.
“Combinatorial barcoding is going to transform the way people do single cell sequencing. It’s simple, elegant, and incredibly scalable,” said Lawrence T. Reiter, PhD and Professor of Neurology at The University of Tennessee Health Science Center. “With Parse Biosciences’ Whole Transcriptome Kit, I’ve been able to finally reveal the neuronal and glial characteristics of our dental pulp stem cell neuron cultures.”
With the launch of the Whole Transcriptome Kit, Parse Biosciences is also making available three datasets encompassing cell lines, brain nuclei, and immune cells. Through these datasets, researchers can see firsthand how the Whole Transcriptome Kit enables highly sensitive gene detection across a wide variety of sample types.
“With these datasets, our goal is to give researchers the ability to explore the capabilities of this technology before they ever bring it into their own labs,” said Charlie Roco, co-founder and CTO of Parse Biosciences. “This is really a whole new level of data, and we want to open it up and use it to inspire researchers. Our goal is that as researchers begin to manipulate our datasets, they realize the extent that single cell sequencing can support them in their research.”
Split Biosciences, now Parse Biosciences, Announces $7M in Series A Funding to Democratize Single-Cell RNA Sequencing
As adoption of scRNA-seq in industry and academia accelerates, Parse Biosciences (formerly Split Bio) offers the most flexible and scalable single cell sequencing kit, no custom instrument needed
Seattle, WA, January 26, 2021
Split Biosciences, a company providing researchers scalable and flexible single cell sequencing solutions, today announced $7M in Series A funding. The funding round was led by Bioeconomy Capital, an early stage VC firm specializing in companies developing life science tools, with participation from new and existing angel investors. Split Bio also announced a rebrand of the company to Parse Biosciences.
The new funding will be used to continue scaling the commercial roll-out of Parse Bioscience’s Whole Transcriptome Kit, which enables researchers to profile up to 100,000 cells in parallel across up to 48 samples. In addition to increased scalability, Parse Biosciences’s technology also provides researchers with higher data quality. Parse enables researchers to increase gene detection in individual cells, while dramatically reducing confounding artifacts that are common in single cell sequencing experiments.
The new brand comes as Parse Biosciences matures beyond the initial academic research upon which the company was founded and in the wake of significant advancements in their technology.
“We have spent the last three years developing a product that more scientists could actually use,” said Charlie Roco, co-founder and CTO of Parse Biosciences. “Our kits are now operating at a higher level than anything else we’ve seen on the market and our company has evolved beyond our original SPLiT-seq method. We wanted our brand to reflect that.”
Researchers in both the pharmaceutical industry and academia have increasingly leveraged single cell technologies to drive discovery. Single cell RNA sequencing continues to transform research across every field of biology and medicine, and the pace of adoption shows no sign of slowing down, with the global single-cell analysis market expected to continue growing at a CAGR of 18% through 2027.
Through single cell sequencing, researchers are able to interrogate biological systems through a new lens, leading to insights that were previously obscured without single cell resolution. To date, however, researchers are limited in their options. While other single cell sequencing solutions on the market require expensive lab equipment, Parse Biosciences has developed a technique that enables single cell sequencing with only basic lab equipment. By removing the most prohibitive barrier to access, the company’s kits help bring single cell sequencing to virtually every research lab around the world.
“From the sheer scalability of their technology, to the entirely unique flexibility that their single cell sequencing kits provides to researchers, Parse Biosciences is creating a new standard for the single cell market,” said Rob Carlson, managing director at Bioeconomy Capital. “We’re excited to back this emerging leader of the industry and support their continued expansion to serve labs all over the world.”
Parse Biosciences enables researchers to scale their single-cell sequencing and achieve more flexible workflows. By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enables samples to be fixed, frozen and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors.
Parse Biosciences’ Whole Transcriptome Kit is already used in 40 labs across the country, providing these researchers with improved resolution and throughput in their experiments. The company also supplies a computational pipeline which generates an experimental report along with a gene-cell count matrix and other processed data that integrates into existing open source tools, such as Seurat and Scanpy.
“At Parse Biosciences, we believe broad and widespread access to tools to understand biology is critical to solving the most pressing health challenges of our generation, from eradicating infectious diseases, to developing successful targeted therapies,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “We know that, as a technology, single cell sequencing holds the key to accelerating progress in human health and scientific research. We’re excited to have Bioeconomy Capital’s support as we continue to scale our offerings to researchers and provide labs with an effective and flexible new technology to support their critical work.”
Split Bio Brings Total Financing to Over $2M
Seattle, WA | August 30th, 2019
Split Bio announced the closing of a bridge financing round, bringing the company’s total funding to over $2M. Split Bio will use these funds to scale-up manufacturing of their Whole Transcriptome Single Cell RNA-sequencing kits. These funds will also support ongoing research and development for follow-on applications.
Split Bio offers the most scalable single cell RNA-sequencing solution, enabling researchers to process up to 100,000 cells across 48 unique samples in parallel. Split Bio’s solution gives users flexibility in their experimental design by allowing them to fix and store cells after sample extraction rather than requiring users to proceed directly to single cell barcoding. This makes it possible to collect biological samples across different days but process all the samples together using a single kit. These standalone kits can be used in any molecular biology lab without the need for custom instruments.
Split Bio is expanding and seeking highly innovative individuals looking to make a large scale impact on the research community. The Seattle based team is currently hiring Research Associates, Scientists, and Computational Biologists. For more information visit the Careers page.
Split Biosciences Awarded Small Business Innovation Research (SBIR) Grant from the National Science Foundation
Small Business Innovation Research Program Provides Seed Funding for R&D
Seattle, WA | July 2, 2019
Split Biosciences has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to further research and development (R&D) work towards democratizing single-cell RNA sequencing.
The Seattle-based company is developing a family of kits that enable researchers to perform scalable single-cell sequencing experiments. Unlike existing single cell technologies, Split Bio’s kits use only standard molecular biology equipment and do not require the upfront purchase of a custom instrument. The company’s innovative approach to single-cell sequencing is based upon a combinatorial barcoding strategy published in Science in 2018.
The one-year grant will pay for continued development on the company’s single-cell RNA-sequencing kit. The kit will enable researchers to sequence up to 100,000 cells across 48 different samples in a single experiment. Researchers interested in participating in an Early Access Program can find more information at splitbio.com.
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.5 million in non-dilutive funds to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the SBIR program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering.
Completion of Seed Financing
Seattle, WA | October 12, 2018
Split Biosciences, a Seattle based single-cell analysis company, today announced the recent completion of its seed financing.
Split Biosciences is a University of Washington spinout and will use the financing to build upon the groundbreaking single-cell RNA-sequencing technology--SPLiT-seq--published in Science in early 2018. The technology addresses current limitations of single-cell RNA-sequencing through the use of multiple rounds of in-situ combinatorial barcoding.